ALX Oncology Holdings Inc.
ALXO
$2.19
$0.041.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.60% | 1.20% | -0.39% | 3.30% | -8.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.21% | -32.17% | -34.39% | -22.36% | -16.33% |
| Operating Income | 29.21% | 32.17% | 34.39% | 22.36% | 16.33% |
| Income Before Tax | 24.59% | 28.55% | 32.00% | 21.77% | 16.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.59% | 28.55% | 32.00% | 21.77% | 16.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.59% | 28.55% | 32.00% | 21.77% | 16.14% |
| EBIT | 29.21% | 32.17% | 34.39% | 22.36% | 16.33% |
| EBITDA | 29.28% | 32.29% | 34.55% | 22.48% | 16.43% |
| EPS Basic | 27.21% | 31.98% | 39.60% | 33.43% | 30.38% |
| Normalized Basic EPS | 29.50% | 33.98% | 41.24% | 33.43% | 30.37% |
| EPS Diluted | 27.21% | 31.98% | 39.60% | 33.43% | 30.38% |
| Normalized Diluted EPS | 29.50% | 33.98% | 41.24% | 33.43% | 30.37% |
| Average Basic Shares Outstanding | 3.48% | 4.69% | 10.52% | 16.31% | 20.69% |
| Average Diluted Shares Outstanding | 3.48% | 4.69% | 10.52% | 16.31% | 20.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |